On the back of a $135 million public offering in February, rare disease gene therapy company Krystal Biotech has launched subsidiary Jeune Inc. to promote its gene therapies for aesthetic skin conditions.
In conjunction with the launch, Jeune announced positive initial Phase I safety data for KB301, now its lead asset. The company said no safety signals or serious adverse events were observed in seven healthy subjects.
Jeune is planning to move KB301 efficacy cohorts later this year in patients with wrinkles and acne scars.
